Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity (NASDAQ:OTLK)
· seekingalpha.com
Outlook Therapeutics leverages an FDA appeal victory for Lytenava amid tight finances and compliance risks. Learn why OTLK stock is a buy.
Outlook Therapeutics, Inc. ( OTLK ) has experienced significant price action over the past two weeks, with shares rebounding from a low of $0.23 to $0.84 as of ...